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Objectives: The loop diuretic bumetanide has been proposed previously as an ad-
junct treatment for neonatal seizures because bumetanide is thought to potentiate 
the action of γ-aminobutyric acid (GABA)ergic drugs such as phenobarbital by pre-
venting abnormal intracellular accumulation of chloride and the subsequent "GABA 
shift." However, a clinical trial in neonates failed to demonstrate such a synergistic 
effect of bumetanide, most likely because this drug only poorly penetrates into the 
brain. This prompted us to develop lipophilic prodrugs of bumetanide, such as the 
N,N-dimethylaminoethyl ester of bumetanide (DIMAEB), which rapidly enter the 
brain where they are hydrolyzed by esterases to the parent compound, as demon-
strated previously by us in adult rodents. However, it is not known whether esterase 
activity in neonates is sufficient to hydrolyze ester prodrugs such as DIMAEB.
Methods: In the present study, we examined whether esterases in neonatal serum 
of healthy term infants are capable of hydrolyzing DIMAEB to bumetanide and 
whether this activity is different from the serum of adults. Furthermore, to extrapo-
late the findings to brain tissue, we performed experiments with brain tissue and 
serum of neonatal and adult rats.
Results: Serum from 1- to 2-day-old infants was capable of hydrolyzing DIMAEB to 
bumetanide at a rate similar to that of serum from adult individuals. Similarly, serum 
and brain tissue of neonatal rats rapidly hydrolyzed DIMAEB to bumetanide.
Significance: These data provide a prerequisite for further evaluating the potential of 
bumetanide prodrugs as add-on therapy to phenobarbital and other antiseizure drugs 
as a new strategy for improving pharmacotherapy of neonatal seizures.
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270 |   THEILMANN ET AL.
1 |  INTRODUCTION
Neonatal seizures represent the most common neurologi-
cal emergency in newborn infants and are associated with 
poor neurodevelopmental outcomes.1-4 Neonatal seizures re-
sult from an underlying cerebral pathology, most frequently 
hypoxic-ischemic encephalopathy (HIE) in term infants. 
Neonatal seizures must be treated promptly because they may 
exacerbate neuronal injury in the immature brain.5 However, 
currently used medications, such as phenobarbital or benzo-
diazepines, are often ineffective, so new treatment strategies 
are urgently needed.1-4 Among newly emerging therapies, 
bumetanide, which has been used safely as a diuretic in neo-
nates, has been proposed to potentiate the antiseizure effi-
cacy of phenobarbital in neonates by an effect on neuronal 
chloride concentrations in the brain.4,6 However, a clinical 
trial failed to demonstrate that bumetanide as an add-on to 
phenobarbital improves seizure control in newborn infants 
with HIE.7
One likely explanation for this negative clinical trial is the 
poor penetration of bumetanide into the brain.8,9 Preclinical 
experiments on plasma and brain levels of bumetanide in 
neonatal and adult rodents have shown that less than 2% of 
the systemic concentration of bumetanide enters the brain 
parenchyma.8,9 This is a consequence of bumetanide's high 
ionization rate in the blood, its extensive binding to plasma 
proteins, and active efflux at the blood-brain barrier (BBB). 
This prompted us to develop lipophilic prodrugs of bumeta-
nide, which easily cross the BBB and are cleaved to bumeta-
nide by carboxylesterases in the brain.10
One of these prodrugs, the N,N-dimethylaminoethylester 
of bumetanide (DIMAEB; see Figure 1) was shown to en-
hance the antiseizure efficacy of phenobarbital in adult rodent 
models of seizures, whereas bumetanide was ineffective.10,11 
In line with our hypothesis, pharmacokinetic experiments in 
mice and rats showed that bumetanide levels in brain tissue 
following systemic administration of DIMAEB are signifi-
cantly higher compared to administration of the parent drug.10 
In vitro experiments with brain homogenates demonstrated 
that DIMAEB is rapidly cleaved to bumetanide.10 Because 
carboxylesterases and other esterases that hydrolyze ester 
prodrugs such as DIMAEB to the parent drug are present not 
only in the brain parenchyma but also in a wide variety of 
tissues and serum12; serum of different species was used as a 
surrogate for DIMAEB cleavage experiments.10 As a result of 
the marked species differences in serum esterase activity,12-14 
DIMAEB was much more rapidly hydrolyzed to bumetanide 
in adult rat and mouse serum than in serum of adult humans, 
which may indicate that the half-life of DIMAEB in humans 
will be much longer than in rodents.10
However, these findings in adults cannot be extrapolated 
directly to neonates because of ontogenetic differences in the 
expression and functional activity of carboxylesterases.14-16 
Key Points
• Neonatal seizures are the most common neuro-
logical emergency in the neonatal period and only 
respond poorly to antiseizure drugs
• In rodents, bumetanide was reported to potenti-
ate phenobarbital, but was ineffective in a clinical 
trial in neonates
• Bumetanide penetrates into the brain only 
poorly, so lipophilic prodrugs such as N,N-
dimethylaminoethylester of bumetanide 
(DIMAEB [BUM5]) may be advantageous
• Here we demonstrate that DIMAEB is cleaved to 
bumetanide by neonatal human and rat serum and 
neonatal rat brain tissue
• These data provide a prerequisite for further eval-
uating the potential of bumetanide prodrugs as 
add-on therapy to phenobarbital in neonates
F I G U R E  1  Chemical structure of bumetanide and its N,N-dimethylaminoethylester (DIMAEB) and hydrolysis of DIMAEB to bumetanide 
by esterases such as carboxylesterase in serum and tissues, including the brain. Whereas bumetanide is highly ionized at physiologic pH (pKa 3.6) 
because of its carboxyl group, this is not the case with DIMAEB, thus favoring the rapid distribution of this prodrug into the brain
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For instance, the hydrolytic activity of two major human car-
boxylesterases hCE1 and hCE2 in liver microsomes of adults 
is about four times higher compared to child microsomes.17 
Similarly, the carboxylesterase activity in liver, plasma, and 
lung of rats is more than three times higher in adult than 
neonatal (7 day) rats.18 On the other hand, compared to fetal 
tissues, there is a postnatal surge in carboxylesterases hCE1 
and hCE2 expression to ensure that the hydrolytic capacity 
rapidly increases after birth.17-20 This has been demonstrated 
by experiments with prodrugs such as oseltamivir (Tamiflu), 
a widely used anti-influenza drug, which is hydrolytically ac-
tivated by carboxylesterase.19
Preliminary experiments in a rat model of birth asphyxia–
induced neonatal seizures indicate that parenteral adminis-
tration of DIMAEB potentiates the antiseizure efficacy of 
phenobarbital, whereas bumetanide is ineffective in this re-
gard (M. Johne, B. Gailus, W. Löscher, unpublished data). 
These data would indicate that DIMAEB enters the neona-
tal brain and is hydrolyzed to bumetanide; however, we did 
not yet study whether DIMAEB is hydrolyzed by neonatal 
brain tissue and serum and whether such hydrolysis can be 
extrapolated to human neonates. Thus the aim of the present 
study was to examine whether human carboxylesterases or 
other esterases in neonatal serum are capable of hydrolyzing 
DIMAEB to bumetanide and whether this activity is different 
from the activity in adults. Furthermore, to study the activ-
ity of esterases directly in brain tissue, we performed experi-
ments with brain tissue and serum of neonatal and adult rats. 
For the experiments with human neonatal serum, we sampled 
blood at day 1 or 2 after birth, because neonatal seizures as a 
result of HIE often occur in the first 1-2 days of life.4 Because 
of the species differences in postnatal brain development, this 
roughly corresponds to postnatal day 10 in rats,21 which was 
therefore used for the present rat experiments.
2 |  MATERIALS AND METHODS
2.1 | Subjects and blood samples
Venous blood was sampled from 20 healthy term male 
and female newborns at day 1 (n = 1) or 2 (n = 19) after 
birth. Blood samples were taken within a venipuncture 
for routine newborn mass screening in the maternity ward 
of the Women's Hospital of Hannover Medical School. 
Declaration of consent for the study was given by the parents 
after comprehensive information. The study was approved 
by the ethics committee of Hannover Medical School (no. 
7877_BO_S_2018).
Blood samples (1 mL per neonate) were stored at room 
temperature for 15-60 minutes in S-Monovette serum tubes 
(Sarstedt) and then centrifuged for 15  minutes at 550 g at 
room temperature. Serum was stored at −20°C for up to 
1  week prior to the in vitro experiments (see below). For 
comparison with the data on neonatal serum, venous blood 
was sampled from two adult female human volunteers (WT, 
CB).
2.2 | Blood and brain samples from animals
Pregnant Sprague-Dawley rats were obtained from Janvier 
(Le Genest-St-Isle). Animals were housed under controlled 
conditions (ambient temperature 22-24°C, humidity 30%-
50%, lights on from 6:00  am to 6:00  pm); food (Altromin 
1324 standard diet) and water were freely available. The rats' 
offspring were sacrificed at postnatal day 10 (P10), which in 
terms of brain development roughly corresponds to that in 
human term babies shortly after birth.21-23 For comparison 
with neonatal data, some experiments were done in adult rats. 
Blood and brain were freshly sampled and serum and brain 
tissue homogenates were used for the in vitro experiments 
described below. All animal experiments were performed ac-
cording to the EU council directive 2010/63/EU and were 
formally approved by the animal subjects review board of 
our institution. All efforts were made to minimize both the 
suffering and the number of studied animals.
2.3 | Synthesis of the N,N-
dimethylaminoethylester of bumetanide
As described previously,10 synthesis of the N,N-
dimethylaminoethylester (or DIMAEB; previously also 
termed “BUM5” or “STS5”) was initiated by penethamate, 
the diethylaminoethyl ester prodrug of benzylpenicillin that 
results in enhanced tissue distribution of this highly ion-
ized antibiotic.24 Synthesis of DIMAEB was based on our 
previous description10 and performed as described in the 
following.
2.3.1 | General methods
All reactions were carried out under positive pressure of 
argon, with oven-dried glassware using standard Schlenk 
techniques. Dry solvents were obtained from Acros Organics 
in Acroseal bottles and used without further purification. 
Bumetanide was purchased from Alfa Aesar and used with-
out further purification. Reactions were monitored by thin-
layer chromatography (TLC; 0.2  mm, silica gel 60, F254, 
aluminium-backed; Machery-Nagel), with detection by UV 
light (254  nm). Flash chromatography was performed on 
Merck silica (60M). Nuclear magnetic resonance (NMR) 
spectra were recorded on an AMX-400 instrument (Bruker) 
at 400  MHz or at 100  MHz for 1H and 13C, respectively. 
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Deuterated methanol and chloroform were used as solvent, 
and spectra were calibrated against the residual solvent peak. 
Data are presented as follows: chemical shift (δ, ppm), mul-
tiplicity (s = singlet, d = doublet, t = triplet, q = quadruplet, 
m = multiplet), coupling constant (reported in Hertz [Hz]), 
and integration.
2.3.2 | Synthesis of DIMAEB
First, the methylester of bumetanide was synthesized 
(Figure 2A). Bumetanide (1.82 g, 5 mmol) was suspended 
and 13 mL of dry MeOH and SOCl2 (800 μL, 11 mmol) was 
added. Reaction mixture was stirred overnight under argon 
atmosphere. After complete conversion (monitored by TLC 
toluene-to-EtOAc ratio, 3:2; Bromocresol green as stain), 
methanol was removed under reduced pressure and residue 
was dissolved in EtOAc. The organic layer was washed with 
saturated aqueous NaHCO3, H2O, and brine. The organic 
layer was then dried over MgSO4, filtered, and solvent re-
moved under reduced pressure. The crude solid was purified 
by recrystallization from EtOH to yield the title compound 
(1.59 g, 4.2 mmol) in 84% yield as a white solid.
NMR spectra of methyl 3-(butylamino)-4-phenoxy-5-sul-
famoylbenzoate: 1H NMR (400  MHz, CDCl3) δ 7.98 (d, 
J = 1.9 Hz, 1H), 7.59 (d, J = 1.9 Hz, 1H), 7.36-7.28 (m, 3H), 
7.11 (t, J = 7.4 Hz, 1H), 6.93 (d, J = 7.8 Hz, 2H), 4.87 (s, 
2H), 4.01-3.95 (m, 1H), 3.94 (s, 3H), 3.11 (t, J = 6.9 Hz, 2H), 
1.48-1.37 (m, 2H), 1.22-1.10 (m, 2H), 0.82 (t, J = 7.3 Hz, 
3H).
For synthesis of 2-(dimethylamino)ethyl 3-(butyl-
amino)-4-phenoxy-5-sulfamoylbenzoate hydrochloride 
(DIMAEB), the methyl ester of bumetanide (222  mg, 
0.59  mmol) was dissolved in 3  mL of N,N-dimethyl-2-
aminoethanol and a catalytic amount of sodium was added 
(Figure  2B). The reaction mixture was heated at 75°C for 
4 hours until no more starting material was present. Volatiles 
were removed under reduced pressure, residue taken up in 
EtOAc, and washed 3 times with H2O, once with brine and 
dried over Na2SO4. The crude product was purified by col-
umn chromatography (EtOAc:Et3N, 4:1), dried thoroughly 
under vacuum, and dissolved in 1:1 mixture of Et2O and H2O. 
One hundred microliters of 1 M aqueous HCl was added and 
volatiles were removed under reduced pressure, giving title 
compound (118 mg, 0.25 mmol) in 42% yield as a white solid.
NMR spectra of 2-(dimethylamino)ethyl 3-(butyl-
amino)-4-phenoxy-5-sulfamoylbenzoate hydrochlo-
ride (DIMAEB): 1H NMR (400  MHz, MeOD) δ 7.94 (d, 
J = 2.0 Hz, 1H), 7.62 (d, J = 2.0 Hz, 1H), 7.35-7.25 (m, 2H), 
7.08 (dd, J = 10.6, 4.2 Hz, 1H), 6.96-6.86 (m, 2H), 4.77-4.67 
F I G U R E  2  Two-step synthesis of DIMAEB. (See text for details)
   | 273THEILMANN ET AL.
(m, 2H), 3.70-3.59 (m, 2H), 3.14 (t, J = 6.8 Hz, 2H), 3.03 (s, 
6H), 1.50-1.37 (m, 3H), 1.15 (dq, J = 14.6, 7.4 Hz, 2H), 0.82 
(t, J = 7.4 Hz, 3H).
2.4 | In vitro cleavage of DIMAEB in the 
serum of humans and rats
Experiments were performed essentially as described previ-
ously for cleavage of DIMAEB in serum of adult humans 
and rats.10 DIMAEB was dissolved in hydroxypropyl-ß-
cyclodextrin (Roquette-Pharma; Frankfurt, Germany), and 
aliquots of 20 µL were added to serum aliquots (0.2-0.3 mL) 
to obtain a drug concentration of 20-40 µg/mL serum. The 
serum aliquots were intermittently stirred and maintained at 
37°C for up to 60 minutes (rats) or 480 minutes (humans), 
respectively. Following the onset of exposure, intermittent 
50 µL samples were taken for analysis of the intact ester and 
cleaved bumetanide as described below.
In pilot experiments, we examined whether storage of 
human serum samples at −20°C has an effect on the activity 
of carboxylesterases. In these tests, it could be confirmed that 
storage had no effect on the cleavage of DIMAEB to bumeta-
nide (data not shown).
2.5 | In vitro cleavage of DIMAEB in brain 
tissue homogenates of rats
Similar to serum, adult brain tissue contains high activities 
of esterases,12 so brain tissue homogenates can be used to 
study whether the esterase activities of neonatal brain are 
already sufficient to cleave DIMAEB. Brains were freshly 
obtained from P10 rats as described above and homoge-
nized in water (about 500  mg tissue in 800  µL). A total 
of 100 µL of the dissolved DIMAEB was added to brain 
homogenate to obtain a drug concentration of 40 µg/g brain 
tissue. The brain homogenate was stirred intermittently and 
maintained at 37°C for 60 minutes. At 0, 0.5, 5, 15, 30, and 
60 minutes following onset of exposure, 100 µL samples 
were taken for analysis of cleaved bumetanide as described 
below.
2.6 | Spontaneous (nonenzymatic) 
hydrolysis of DIMAEB in water
Carboxylic esters can hydrolyze spontaneously in water with 
increasing temperature.25 Thus we performed a control ex-
periment in which we added DIMAEB to water (pH adjusted 
to 7.35) and exposed the solution at 37°C for 480 minutes. 
All details were as described above for serum.
2.7 | Analysis of DIMAEB and bumetanide 
in water, serum and brain homogenates
Bumetanide was analyzed in water, serum, and brain by high-
performance liquid chromatography (HPLC) with ultraviolet 
detection (UV) as recently described in detail.10,26 The same 
method was used with a modified composition of the mobile 
phase (0.05  M phosphate buffer/acetonitrile 30:70 instead 
of 70:30; see below) for determination of DIMAEB. As is 
standard for HPLC analysis, we used a commercial solution 
F I G U R E  3  In vitro hydrolysis of the bumetanide ester DIMAEB to bumetanide in human serum. Data for neonates (age 1-2 d) are separately 
shown as means ± standard error of the mean (SEM) of 10 male and 10 female neonates, respectively. For comparison, the average data of two 
female adults are shown. (A) Degradation of DMAEB in human serum, illustrated as percent decline from the initial concentration. (B) Formation 
of bumetanide from DIMAEB in human serum, illustrated as percent relative to the initial concentration of DIMAEB
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(0.5  mg/mL) of the sodium salt of bumetanide (Burinex), 
which was kindly provided by Leo Pharma.
In short, 50 µL of serum was mixed with 150 µL methanol 
and then centrifuged for 3 minutes at 13 400 g. Aliquots of the 
supernatant were injected into the HPLC apparatus equipped 
with a Nucleosil 120-5 C18 pre-column (60  ×  4  mm; 
Knauer), a Nucleosil 120-5 C18 column (250 × 4.6 mm), and 
a UV detector (at 210  nm). The mobile phase, which was 
pumped with a flow rate of 1 mL/min, was composited of 
0.05 M phosphate buffer and acetonitrile in a proportion of 
70:30 (for DIMAEB 30:70); the pH was adjusted at 5.6. The 
same HPLC conditions were used for analysis of DIMAEB 
and bumetanide in brain tissue samples.
For analysis of DIMAEB and bumetanide in brain tis-
sue, brain tissue homogenate aliquots were centrifuged for 
20 minutes at 21 881 g, and the supernatant was purified by 
solid phase extraction using a Chromabond HR-X column 
(Macherey-Nagel; Düren; Germany). Compounds were ex-
tracted from the column by methanol, the extract was evap-
orated to dryness by nitrogen, the residue was dissolved in 
100 µL buffer, and 20 µL was used for HPLC analysis. The 
detection limit for bumetanide was about 50 ng/mL in plasma 
and 100 ng/g (=0.28 µM) in brain tissue.
3 |  RESULTS
3.1 | Experiments with human serum
Data from the one infant in whom blood was sampled at day 1 
after birth did not differ from those in whom blood was taken 
2 days after birth, so data were analyzed together and illustrated 
in Figure  3. Because gender differences in the hydrolysis of 
ester prodrugs by carboxylesterases have been reported,27 data 
on hydrolysis of DIMAEB in neonatal serum samples are il-
lustrated separately for both genders (Figure 3). As shown in 
Figure  3A, DIMAEB was metabolized in neonatal serum at 
about the same rate in both genders; 50% degradation was ob-
tained at about 7 hours. In parallel to the reduction in DIMAEB 
levels, bumetanide levels increased in the neonatal serum of 
both genders (Figure 3B). Unexpectedly, the rate of DIMAEB 
hydrolysis in neonatal serum was not slower than the rate in 
adult serum (Figure 3A). Furthermore, formation of bumetanide 
was considerably faster and much more pronounced in neonatal 
serum compared to adult serum (Figure 3B).
3.2 | Experiments with rat serum
In serum of neonatal (postnatal day 10) rats, DIMAEB was 
much more rapidly metabolized (Figure 4A) than in human 
neonatal serum (Figure 3A). Indeed, complete (100%) degra-
dation occurred within 15-30 minutes in neonatal rat serum 
without any obvious sex difference. As shown in Figure 4B, 
DIMAEB was rapidly hydrolyzed to bumetanide in neona-
tal rat serum. Compared to neonatal rat serum, hydrolysis of 
DIMAEB to bumetanide was even more rapid in adult rat 
serum (Figure 4A,B), confirming previous data.10
3.3 | Experiments with rat brain 
homogenates
In neonatal rat brain homogenates, bumetanide formation from 
DIMAEB (Figure 5) was less rapid than in neonatal rat serum 
(Figure 4). About 50%–70% of DIMAEB was hydrolyzed to 
bumetanide within 60 minutes. In comparison to neonatal rat 
brain homogenates, hydrolysis of DIMAEB to bumetanide 
F I G U R E  4  In vitro hydrolysis of the 
bumetanide ester DIMAEB to bumetanide in 
rat serum. Data for neonatal rats (age 10 d) 
are shown separately for male and female 
animals as means from pooled samples. For 
comparison, average data of six female adult 
rats are shown. (A) Degradation of DMAEB 
in rat serum, illustrated as percent decline 
from the initial concentration. (B) Formation 
of bumetanide from DIMAEB in rat serum, 
illustrated as percent relative to the initial 
concentration of DIMAEB
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appeared to be more rapid in brain homogenates from adult ani-
mals, although the difference was only moderate.
3.4 | Control experiment with water
Spontaneous (nonenzymatic) hydrolysis of DIMAEB at 37°C 
was determined in water at pH 7.35. Within 480  minutes, 
the DIMAEB concentration was reduced by 34% (±0.84%; 
n = 3), on average, because of spontaneous hydrolysis to bu-
metanide (data not shown). As shown in Figure 3, respective 
figures for neonatal human serum were 53% (male) and 56% 
(female), indicating that ~60% of the hydrolysis observed in 
human serum was nonenzymatic. Nonenzymatic hydrolysis 
did obviously not play any significant role for neonatal rat 
serum, because almost complete hydrolysis of DIMAEB oc-
curred within 5-15 minutes (Figure 4A). In contrast to non-
enzymatic hydrolysis of DIMAEB in water at 37°C, such 
neutral hydrolysis was not observed when solutions were 
kept at low temperatures.
4 |  DISCUSSION
Carboxylesterases (or carboxylic-ester hydrolases; EC 
3.1.1.1) are major hydrolytic enzymes responsible for the 
metabolism of numerous carboxylic acid esters, carbamates, 
thioesters, and amide agents.28 In humans, three carboxy-
lesterases have been identified, although human carboxy-
lesterase1 (hCE1) and human carboxylesterase 2 (hCE2) 
are the two extensively studied isoenzymes involved in 
xenobiotic metabolism.28 Both isoenzymes play crucial 
roles in the hydrolysis and bioactivation of various ester 
prodrugs such as oseltamivir, clopidogrel, irinotecan, and 
capecitabine.28 When designing DIMAEB, we thought that 
this lipophilic prodrug of bumetanide would rapidly cross 
the BBB and would be hydrolyzed by carboxylesterases 
in the brain to bumetanide. This assumption was subse-
quently confirmed by in vivo and in vitro experiments 
in adult rodents.10 In the current study we demonstrate 
that neonatal brain tissue is also capable of hydrolyzing 
DIMAEB to bumetanide to a an extent similar to that in 
adult brain tissue. Furthermore, by using human neonatal 
serum as a surrogate for brain tissue, we show that serum 
from 1- to 2-day-old infants is capable of hydrolyzing 
DIMAEB to bumetanide at a rate similar to that of serum 
from adult individuals.
The latter finding was unexpected, because experiments 
with liver tissue samples and liver microsomes have indicated 
that the hydrolytic activity of carboxylesterases of adults is 
higher than that of children and neonates when using pro-
drugs such as oseltamivir as a substrate.17,19 However, the 
hydrolytic activity of carboxylesterases is dependent on the 
substrate,28 so ontogenetic differences in drug hydrolysis 
cannot be extrapolated to different prodrugs. Furthermore, 
Shi et al19 and Chen et al20 reported a postnatal surge in car-
boxylesterase hCE1 and hCE2 expression and activity in 
human neonates, which may be important to enable the infant 
to detoxify potentially harmful endogenous and exogenous 
compounds early after birth. As shown by Shi et al,19 the 
postnatal surge in hCE1 can be used to hydrolytically acti-
vate ester prodrugs such as the widely used anti-influenza 
drug oseltamivir. The present data indicate that the postnatal 
surge of carboxylesterases can also be used to activate the 
ester prodrug DIMAEB. Thus this new compound might con-
stitute as a novel strategy for potentiating the efficacy of phe-
nobarbital in treatment of neonatal seizures. In this respect, 
it is interesting to note that phenobarbital has been reported 
to induce neonatal carboxylesterases.29 As mentioned in the 
Introduction, promising data from preliminary experiments 
in a rat model of birth asphyxia–induced neonatal seizures 
indicate that parenteral administration of DIMAEB potenti-
ates the antiseizure efficacy of phenobarbital, whereas bu-
metanide is not effective (M. Johne, B. Gailus, W. Löscher, 
unpublished data).
We cannot exclude that DIMAEB was hydrolyzed by ester-
ases other than carboxylesterases in human and rat serum and 
rat brain. Esterases, that is, hydrolases that split ester bonds 
in human blood, have an important role in the disposition of 
drugs. They participate in the activation of ester prodrugs 
F I G U R E  5  In vitro hydrolysis of the bumetanide ester DIMAEB 
to bumetanide in rat brain homogenates. Data for neonatal rats (age 
10 d) are shown separately for male and female animals as means from 
pooled samples. For comparison, average data (±SEM) of six female 
adult rats are shown. Data are illustrated in percent bumetanide relative 
to the initial concentration of DIMAEB
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but may also inactivate drugs and detoxify natural and syn-
thetic ester–containing poisons.30-32 Blood serum or plasma 
contains different esterases, including butyrylcholinesterase 
(EC 3.1.1.8), paraoxonase (EC 3.1.8.1), acetylcholinesterase 
(EC 3.1.1.7) and other cholinesterases, carboxylesterase (EC 
3.1.1.1) and albumin, which has been proven to act as an es-
terase.30,31 Data on the relative activities of these esterases in 
serum or plasma of humans and experimental animals are con-
tradictory. However, more recent studies consistently found 
that carboxylesterase activity in human plasma or serum is low, 
whereas it is high in rodent serum.12,32-40 Nevertheless, signif-
icant carboxylester-hydrolyzing enzyme activity is present in 
human serum or plasma, both in neonates and adults,12,33-35 
which is also demonstrated by the current study.
In addition to enzymatic hydrolysis in serum and brain ho-
mogenates, we found that DIMAEB is also hydrolyzed sponta-
neously in water at body temperature. “Neutral” hydrolysis of 
simple carboxylic esters in water at increased temperatures is 
a well-known phenomenon, but typically is much slower than 
enzymatic hydrolysis.25 This was also observed in the pres-
ent study. Nevertheless, particularly in case of neonatal human 
serum, nonenzymatic hydrolysis certainly contributed to the 
overall hydrolysis of DIMAEB to bumetanide determined in 
the present study.
One potential disadvantage of lipophilic ester prodrugs 
such as DIMAEB is that although increased lipophilicity may 
improve movement across the BBB, it also tends to increase 
uptake into other tissues, causing an increased tissue bur-
den.41,42 However, by comparing diverse prodrugs of bumeta-
nide, DIMAEB was shown to achieve the highest bumetanide 
brain levels, whereas diuretic activity was lower than that of 
bumetanide, a finding that would argue against unspecific tis-
sue distribution.10 There are several promising examples of 
ester-linked prodrugs for enhancing CNS delivery, which is 
the most commonly employed approach for increasing lipo-
philicity of polar molecules exhibiting limited CNS penetra-
tion.42,43 The high CNS delivery of lipophilic ester prodrugs 
is a consequence of the high cerebral blood flow, which rep-
resents about 15%–20% of the cardiac output, even though 
the brain represents only 2% of the body weight.44,45 Thus 
relative brain perfusion is higher than perfusion of most other 
organs and tissues, which enables small, lipophilic prodrugs 
to penetrate into the brain parenchyma rapidly.
In summary, the present study shows that neonatal serum 
and rat brain tissue are capable of rapidly hydrolyzing the bu-
metanide ester prodrug DIMAEB to bumetanide. These data are 
a prerequisite for further evaluation of the potential of bumeta-
nide ester prodrugs as add-on to phenobarbital and other anti-
seizure drugs as a new strategy for improving pharmacotherapy 
of neonatal seizures. The positive interaction between bumeta-
nide and GABAergic drugs such as phenobarbital is thought 
to be a consequence of the inhibitory effect of bumetanide on 
the sodium/potassium/chloride cotransporter NKCC1 in brain 
neurons, although other mechanisms may contribute to the in-
teraction.4,6,9 An advantage of prodrugs of clinically approved 
drugs such as bumetanide is that the drug development pipeline 
to first use in humans is much shorter compared to new chem-
ical entities.42,46 Currently, about 10% of pharmaceutical prod-
ucts are used as prodrugs, nearly half of them being converted to 
the active form by hydrolysis, mainly by ester hydrolysis, which 
demonstrates the success of this strategy.47 DIMAEB provides a 
useful tool to further improve the bumetanide prodrug strategy 
for neurological indications, such as neonatal seizures, in which 
NKCC1 inhibitors are thought to be useful.
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